In an exclusive video interview with PropThink.com, Ablynx (EBR:ABLX)(OTC:ABLYF) CEO Dr. Edwin Moses discusses the company’s platform Nanobody technology – 1/10th the size of traditional anti-bodies – and the broad indications in which their compounds may prove beneficial. Ablynx has created a unique development and production strategy that relies on partnership agreements – Merck Serono (NYSE:MRK), Novartis (NYSE:NVS) – for commercialization of their products. The company has raised more than €200M in equity financing and over €160M through partnership milestones and royalties, but has no commercial arm of their own.
Dr. Moses says the company has one orphan drug that they may take through commercialization alone – a first – and 25 projects in various stages of pipeline development. He discusses the importance of intellectual property for Ablynx and the company’s promising Phase I pulmonary product that he believes may be a first of its kind.
